Translational gastrointestinal pharmacology in the 21st century: 'The lesogaberan story'

Current Opinion in Pharmacology

Volumn 11, Issue 6, 2011, Pages 630-633

  Boeckxstaens, Guy E ^a   Denison, Hans ^b   Jensen, Jörgen M ^b   Lehmann, Anders ^b   Ruth, Magnus ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADX 10059; AZD 2066; BACLOFEN; DRONABINOL; LESOGABERAN; METABOTROPIC RECEPTOR ANTAGONIST; PLACEBO; PROTON PUMP INHIBITOR; STOMACH SECRETION INHIBITOR; UNCLASSIFIED DRUG;

ADD ON THERAPY; ARTICLE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG PENETRATION; DRUG TARGETING; GASTROESOPHAGEAL REFLUX; HUMAN; LOWER ESOPHAGUS SPHINCTER; NONHUMAN; PRIORITY JOURNAL; SMOOTH MUSCLE RELAXATION;

EID: 82255175631     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2011.10.011     Document Type: Review

References (25)

1. H. El-Serag, A. Becher, and R. Jones Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies Aliment Pharmacol Ther 32 2010 720 737
2. C. Donnellan, N. Sharma, C. Preston, and P. Moayyedi Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease Cochrane Database Syst Rev 2005 CD003245
3. P.J. Kahrilas, C.W. Howden, and N. Hughes Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux disease Am J Gastroenterol 106 2011 1419 1425
4. G.E. Boeckxstaens, and A. Smout Systematic review: role of acid, weakly acidic and weakly alkaline reflux in gastroesophageal reflux disease Aliment Pharmacol Ther 32 2010 334 343
5. L.A. Blackshaw, E. Staunton, A. Lehmann, and J. Dent Inhibition of transient LES relaxations and reflux in ferrets by GABA receptor agonists Am J Physiol 277 1999 G867 G874
6. A. Lehmann, M. Antonsson, M. Bremner-Danielsen, M. Flardh, L. Hansson-Branden, and L. Karrberg Activation of the GABA(B) receptor inhibits transient lower esophageal sphincter relaxations in dogs Gastroenterology 117 1999 1147 1154 (Pubitemid 29512674)
7. A. Lehmann, M. Antonsson, A.A. Holmberg, L.A. Blackshaw, L. Branden, H. Brauner-Osborne, B. Christiansen, J. Dent, T. Elebring, and B.M. Jacobson (R)-(3-amino-2-fluoropropyl) phosphinic acid (AZD3355), a novel GABA(B) receptor agonist, inhibits transient lower esophageal sphincter relaxation through a peripheral mode of action J Pharmacol Exp Ther 331 2009 504 512
8. I. Lidums, A. Lehmann, H. Checklin, J. Dent, and R.H. Holloway Control of transient lower esophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in normal subjects Gastroenterology 118 2000 7 13 (Pubitemid 30020367)
9. Q. Zhang, A. Lehmann, R. Rigda, J. Dent, and R.H. Holloway Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-oesophageal reflux disease Gut 50 2002 19 24 (Pubitemid 34028297)
10. M.A. van Herwaarden, M. Samsom, and A.J. Smout Excess gastroesophageal reflux in patients with hiatus hernia is caused by mechanisms other than transient LES relaxations Gastroenterology 119 2000 1439 1446 (Pubitemid 32198668)
11. K.J. Lee, R. Vos, J. Janssens, and J. Tack Differential effects of baclofen on lower oesophageal sphincter pressure and proximal gastric motility in humans Aliment Pharmacol Ther 18 2003 199 207 (Pubitemid 36951656)
12. H. Beaumont, A. Smout, M. Aanen, H. Rydholm, A. Lei, A. Lehmann, M. Ruth, and G. Boeckxstaens The GABA(B) receptor agonist AZD9343 inhibits transient lower oesophageal sphincter relaxations and acid reflux in healthy volunteers: a phase I study Aliment Pharmacol Ther 30 2009 937 946
13. L. Branden, A. Fredriksson, E. Harring, J. Jensen, and A. Lehmann The novel, peripherally restricted GABA(B) receptor agonist lesogaberan (AZD3355) inhibits acid reflux and reduces esophageal acid exposure as measured with 24-h pHmetry in dogs Eur J Pharmacol 634 2010 138 141
14. G.E. Boeckxstaens, H. Rydholm, A. Lei, J. Adler, and M. Ruth Effect of lesogaberan, a novel GABA(B)-receptor agonist, on transient lower esophageal sphincter relaxations in male subjects Aliment Pharmacol Ther 31 2010 1208 1217
15. G.E. Boeckxstaens, H. Beaumont, V. Mertens, H. Denison, M. Ruth, J. Adler, D.G. Silberg, and D. Sifrim Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease Gastroenterology 139 2010 409 417
16. P. Miner, D.G. Silberg, M. Ruth, F. Miller, and J. Pandolfino Effect of multiple doses of lesogaberan, a novel GABAB agonist, on reflux episodes in patients with GERD with symptoms despite proton pump inhibitor treatment Gastroenterology 140 Suppl 1 2011 S-578
17. H. Beaumont, J. Jensen, A. Carlsson, M. Ruth, A. Lehmann, and G. Boeckxstaens Effect of delta9-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans Br J Pharmacol 156 2009 153 162
18. W.O. Rohof, A. Lei, D. Hirsch, M. strand, L. Ny, M.B. Hansen, and G. Boeckxstaens Effect of a novel matabotropic glutamate receptor 5 antagonist (AZD2066) on transient lower esophageal sphicter relaxations and reflux episodes in healthy males Gastroenterology 140 Suppl 1 2011 S-66
19. G.E. Boeckxstaens, H. Beaumont, J.G. Hatlebakk, D.G. Silberg, K. Bjorck, M. Karlsson, and H. Denison A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial Gut 60 2011 1182 1188
20. N.J. Shaheen, H. Denison, K. Björck, M. Karlsson, and D. Silberg Efficacy of a novel γ-aminobutyric acid type B receptor (GABAB) agonist, lesogaberan, as an add-on to proton pump inhibitor (PPI) therapy in the treatment of gastroesophageal reflux disease in patients who have a partial response to PPI therapy Gastroenterology 140 Suppl 1 2011 S-580
21. M. Shaw, J. Dent, T. Beebe, O. Junghard, I. Wiklund, T. Lind, and F. Johnsson The reflux disease questionnaire: a measure for assessment of treatment response in clinical trials Health Qual Life Outcomes 6 2008 31
22. N. Vakil, D. Silberg, K. Björck, K. Halling, J. Paty, M. Karlsson, H. Denison, and A. Rydén Validation of a patient reported outcome instrument, the Reflux Symptom Questionnaire electronic Diary (RESQ-eD), in patients with a partial response to PPI therapy Gastroenterology 140 Suppl 1 2011 S-67
23. D.O. Castell, F. Zerbib, S. Bruley des Varnnes, J.P. Galmiche, M.F. Vaezi, and C. Keywood Efficacy and tolerability of ADX10059, a mGluR5 negative allosteric modulator, as add on therapy to proton pump inhibitors (PPIs) in patients with gastroesophageal reflux disease (GERD) Gastroenterology 140 Suppl 1 2011 S-557
24. N.B. Vakil, F.J. Huff, A. Bian, D.S. Jones, and D. Stamler Arbaclofen placarbil in GERD: a randomized, double-blind, placebo-controlled study Am J Gastroenterol 106 2011 1427 1438
25. A.J. Page, and L.A. Blackshaw Roles of gastro-oesophageal afferents in the mechanisms and symptoms of reflux disease Handb Exp Pharmacol 194 2009 227 257